Antidiabetic Drugs Show Promise in Reducing Cancer Risk for Type 2 Diabetes Patients

Recent research conducted by Li-Yun Duan and colleagues at Guang'anmen Hospital in Beijing, China, suggests that certain antidiabetic drugs may have a protective effect against cancer in patients with type 2 diabetes mellitus (T2DM). The study, published in the World Journal of Diabetes, involved a systematic review and network meta-analysis of 87 high-quality studies involving 216,106 patients and 26 different drugs across seven classes.

Key Takeaways:

• The research found that antidiabetic drugs did not increase the overall risk of cancer compared to placebo, contradicting previous studies.
• Certain antidiabetic medications demonstrated a more pronounced advantage in reducing cancer risk, including dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter type 2 inhibitors, sulfonylureas, biguanides, insulin, and glucagon-like peptide-1 receptor agonists.
• The study suggests that specific antidiabetic drugs may offer protective effects against certain cancers, such as thyroid, rectal, lung, and breast cancers.
• Researchers emphasize that more large-scale, high-quality clinical trials are required to validate the findings and optimize comprehensive cancer management strategies for patients with T2DM.

Statistics:

• The study included 13535 articles, with 87 high-quality studies and 216106 patients.
• The analysis involved 26 different antidiabetic drugs across seven classes.
• The researchers found that certain antidiabetic medications reduced cancer risk by 10-30% in various populations.
• The study's findings were based on a systematic review of 87 high-quality studies, with 16 studies specifically evaluating the relationship between antidiabetic drugs and cancer risk.

Sources:

• Association between antidiabetic drugs and cancer risk in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis. World Journal of Diabetes, 2025;16(10):110174.
• World Journal of Diabetes. Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, Ca, United States.